PROTILUP 200ML SYR India - English - Central Drugs Standard Control Organization

protilup 200ml syr

lupinova - lysine hcl,protein hydrolysate,carbohydrate,niacinamide,fe choline citrate,mgcl2,zn sulphate - syr - 20mg,0.333g,3g,10mg,15mg,0.333mg,2.7mg - 200ml

In-line arterial blood sampling set Australia - English - Department of Health (Therapeutic Goods Administration)

in-line arterial blood sampling set

livanova australia pty ltd - 45760 - in-line arterial blood sampling set - the hms bs range of sterile in-line arterial blood sampling kits consist of pvc tubing, luer connections, various stop cocks, reservoir and a drip chamber, connected to various numbers of hms pressure transducers. hms bs kits are intended to be used for sampling of undiluted blood and to measure blood pressure/s of a patient, to be transmitted to the patient monitor in the or or icu. the hms bs kit without hms pressure transducer can be connected to other manufacturer's pressure transducer to acheive kit with blood sampling function.

In-line arterial blood sampling set Australia - English - Department of Health (Therapeutic Goods Administration)

in-line arterial blood sampling set

itl australia pty ltd - 45760 - in-line arterial blood sampling set - the blood pressure monitoring & blood sampling kit is intended for invasive measurement of blood pressure and needle free in -line sampling of undiluted arterial blood in different compartments of the circulatory system.

Docetaxel Accord European Union - English - EMA (European Medicines Agency)

docetaxel accord

accord healthcare s.l.u. - docetaxel - head and neck neoplasms, carcinoma, non-small-cell lung, adenocarcinoma, prostatic neoplasms, breast neoplasms - antineoplastic agents, - breast cancerdocetaxel accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.docetaxel accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer w

Lopinavir/Ritonavir Mylan European Union - English - EMA (European Medicines Agency)

lopinavir/ritonavir mylan

mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

Sofradex Ear/Eye Drops, solution Malta - English - Medicines Authority

sofradex ear/eye drops, solution

sanofi malta limited - framycetin sulfate, dexamethasone, gramicidin - ear drops, solution, eye drops, solution - framycetin sulfate 0.5 percent weight/volume ; dexamethasone 0.05 percent weight/volume ; gramicidin 0.005 percent weight/volume - ophthalmological and otological preparations

Sofradex Ear/Eye Drops, solution Malta - English - Medicines Authority

sofradex ear/eye drops, solution

sanofi s.r.l viale l. bodio, 37/b 20158, milan, italy - framycetin sulfate, dexamethasone, gramicidin - eye drops, solution ear drops, solution - framycetin sulfate 0.5 % (w/v) dexamethasone 0.05 % (w/v) gramicidin 0.005 % (w/v) - ophthalmological and otological preparations